Genetic Disease Clinical Trials

58 recruitingLast updated: June 18, 2026

There are 58 actively recruiting genetic disease clinical trials across 29 countries. Studies span Not Applicable, Phase 3, Phase 2. Top locations include Boston, Massachusetts, United States, Paris, France, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Genetic Disease Trials at a Glance

58 actively recruiting trials for genetic disease are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Not Applicable with 14 trials, with the heaviest enrollment activity in Boston, Paris, and Philadelphia. Lead sponsors running genetic disease studies include Boston Children's Hospital, Children's Hospital of Philadelphia, and Imagine Institute.

Browse genetic disease trials by phase

Treatments under study

About Genetic Disease Clinical Trials

Looking for clinical trials for Genetic Disease? There are currently 42 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Genetic Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Genetic Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 58 trials

Recruiting

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Genetic diseasesFeverROSAH+4 more
National Human Genome Research Institute (NHGRI)5,000 enrolled5 locationsNCT00001373
Recruiting

Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network

Genetic Disease
National Human Genome Research Institute (NHGRI)20,000 enrolled33 locationsNCT02450851
Recruiting

Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

GranulomaGranulomatous Disease, ChronicLeukocyte Disease+2 more
National Institute of Allergy and Infectious Diseases (NIAID)850 enrolled1 locationNCT00001405
Recruiting

UW Undiagnosed Genetic Diseases Program

Genetic DiseaseRare DiseasesUndiagnosed Disease
University of Wisconsin, Madison1,000 enrolled1 locationNCT04586075
Recruiting
Not Applicable

Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions

Genetic DiseaseRare Genetic DisordersNonverbal Communication+2 more
Murdoch Childrens Research Institute38 enrolled1 locationNCT07039084
Recruiting
Phase 3

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Muscular Dystrophy, DuchenneDMDNeuromuscular Diseases (NMD)+10 more
Dyne Therapeutics90 enrolled1 locationNCT07608432
Recruiting

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Genetic DiseaseAutoimmune DiseasesNeurological Diseases or Conditions+1 more
Imagine Institute500 enrolled32 locationsNCT07040774
Recruiting

Developing Protocols for Modelling of Genetic Diseases Using Induced Pluripotent Stem Cells

Genetic Disease
Sapna Vyas3,000 enrolled1 locationNCT03612310
Recruiting

Genetic Disorders of Obesity Program Database

Genetic DiseaseObesity, Childhood
Baylor College of Medicine500 enrolled1 locationNCT05747976
Recruiting
Not Applicable

Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases

Rare Genetic Disease
Assistance Publique Hopitaux De Marseille62 enrolled1 locationNCT07075107
Recruiting

Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders

Genetic DiseaseInherited Disease
The Hospital for Sick Children200 enrolled1 locationNCT05386134
Recruiting

The Natural History of Mitochondrial Diseases

Genetic DiseaseMitochondrial DiseasesNeurological Diseases or Conditions
Neuroscience Research Australia500 enrolled1 locationNCT06504433
Recruiting
Phase 3

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Nervous system diseasePeripheral nervous system diseaseAmyloidosis+17 more
Intellia Therapeutics60 enrolled14 locationsNCT06672237
Recruiting

Characterization and Contribution of Genome-wide DNA Methylation (DNA Methylation Episignatures) in Rare Diseases With Prenatal Onset

Congenital MalformationRare Fetal Genetic Diseases
Assistance Publique - Hôpitaux de Paris63 enrolled1 locationNCT06475651
Recruiting
Phase 3

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Beta-ThalassemiaSickle Cell DiseaseHematologic Diseases+4 more
Vertex Pharmaceuticals Incorporated26 enrolled6 locationsNCT05477563
Recruiting

Molecular Diagnosis of Systemic Autoinflammatory Diseases

Genetic DiseaseMolecular Pathway DeregulationSomatic Mutation+2 more
Institut National de la Santé Et de la Recherche Médicale, France300 enrolled1 locationNCT05364294
Recruiting

PKP2-ACM Natural History Study

Genetic diseasesCardiomyopathiesCardiovascular Diseases+1 more
Rocket Pharmaceuticals Inc.36 enrolled3 locationsNCT06644742
Recruiting

CUHK Stroke Biobank

Stroke, IschemicGenetic DiseaseAtherosclerosis, Cerebral
Chinese University of Hong Kong500 enrolled1 locationNCT03291392
Recruiting

Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome

Genetic DiseaseChopra-Amiel-Gordon SyndromeCAGS+1 more
Boston Children's Hospital125 enrolled1 locationNCT05528744
Recruiting

Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk

Genetic Disease
Women's Hospital School Of Medicine Zhejiang University1,000,000 enrolled1 locationNCT07365254